Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2538 - Exploratory analysis of baseline microsatellite instability (MSI) status in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) or placebo in the phase 3 CORRECT trial

Date

09 Sep 2017

Session

Poster display session

Presenters

Karl Köchert

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

K. Köchert1, G. Beckmann2, M. Teufel3

Author affiliations

  • 1 Genomics And Biomarker Statistics, Bayer AG, 13353 - Berlin/DE
  • 2 Bioinformatics, Bayer AG, 13342 - Berlin/DE
  • 3 Translational Medicine Oncology, Bayer HealthCare Pharmaceuticals, 07981 - Whippany/US
More

Resources

Abstract 2538

Background

A high degree of MSI (MSI-H) has been associated with a good prognosis in early-stage CRC. However, emerging evidence suggests that MSI-H patients may have a worse response to chemotherapy in the metastatic setting. Here, we evaluate survival outcomes by baseline MSI status in patients with mCRC in the CORRECT phase 3 trial.

Methods

CORRECT was an international, multicenter, placebo-controlled trial of 760 patients with treatment-refractory mCRC. Patients were randomized 2:1 to receive oral REG 160 mg or placebo once daily for Weeks 1–3 of each 4-week cycle. Subgroup analysis included patients in the safety population (≥1 dose of study drug) who consented to genetic biomarker studies and from whom archival tissue was available. Next-generation sequencing of archival tumor was performed using the FoundationONE gene panel (Foundation Medicine, Cambridge, MA). Overall survival (OS) and progression-free survival (PFS) by MSI status and its potential interaction with treatment were assessed by a Cox proportional hazards model and Kaplan–Meier analysis.

Results

Archival tumor tissue was available for 229 of the 760 randomized patients (Table). Of the 229 patients, 42 (18%) were MSI-H and 187 (82%) were non-MSI-H, 62% were male, 57%/43% were ECOG performance status 0/1, 58% had a KRAS mutation, and 3% had a BRAF mutation. Although there was less clinical benefit in patients in the MSI-H subgroup, no significant association was detected between MSI status and treatment interaction with OS or PFS in the multivariate analysis (P = 0.15).Table:

534P

MSI-H (n = 42)Non-MSI-H (n = 187)
Regorafenib, n (%)27 (64)114 (61)
Placebo, n (%)15 (36)73 (39)
Overall survival, HR (95% CI)0.97 (0.45, 2.07)0.78 (0.53, 1.15)
Progression-free survival, HR (95% CI)0.78 (0.39, 1.56)0.48 (0.35, 0.67)

CI, confidence interval; HR, hazard ratio

Conclusions

This retrospective exploratory analysis of a small subgroup of patients with mCRC from CORRECT shows a prevalence of MSI-H at ∼15-20% and no interaction between MSI status and REG treatment benefit. Due to small sample sizes in the subgroups no firm conclusions can be drawn and further studies are necessary to assess the correlation of MSI status with REG clinical benefit.

Clinical trial identification

NCT01103323

Legal entity responsible for the study

Bayer

Funding

Bayer

Disclosure

K. Köchert, G. Beckmann: Employment: Bayer. M. Teufel: Stocks and employment: Bayer.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings